Clinical Utility of Preoperative Vitamin D3 Injection for Preventing Transient Hypocalcemia after Total Thyroidectomy
Table 3
Comparison of baseline clinicopathologic characteristics of patients with transient hypocalcemia between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN) groups.
VDI (n = 67)
VDN (n = 571)
value
Age (years)
46.1 ± 14.1 (range, 16–78)
45.0 ± 13.7 (range, 8–84)
0.538
Female
54 (80.6%)
460 (80.6%)
0.967
Multifocality
42 (62.7%)
331 (58.0%)
0.513
Bilaterality
31 (46.3%)
266 (46.6%)
0.961
ETE
18 (26.9%)
97 (17.0%)
0.063
Operation time (min)
176.7 ± 210.3 (range, 48–490)
150.7 ± 70.4 (range, 50–635)
0.034
Hospital stay (day)
4.1 ± 1.2 (range, 3–7)
3.9 ± 1.5 (range, 2–23)
0.315
Tumor size (cm)
1.4 ± 1.2 (range, 0.2–6.3)
1.3 ± 0.9 (range, 0.2–10.5)
0.404
T stage
0.135
T1
43 (64.2%)
424 (74.3%)
T2
6 (8.9%)
46 (8.0%)
T3
3 (4.5%)
34 (6.0%)
T4a
15 (22.4%)
65 (11.4%)
T4b
0 (0%)
1 (0.2%)
N stage
0.129
N0
23 (34.3%)
192 (33.6%)
N1a
16 (23.9%)
199 (34.9%)
N1b
28 (41.8%)
180 (31.5%)
M stage
0.028
M1
3 (4.5%)
4 (0.7%)
TNM stage
0.608
Stage I
51 (76.1%)
475 (83.2%)
Stage II
13 (19.4%)
78 (16.7%)
Stage III
3 (4.5%)
15 (2.6%)
Stage IVa
0 (0%)
1 (0.2%)
Stage IVb
0 (0%)
1 (0.2%)
Data are expressed as patient’s number (%), or mean ± SD. A statistically significant difference was defined as < 0.05. ETE, extrathyroidal extension; T, tumor; N, node; M, metastasis.
